What is prostate cancer?
Prostate cancer is a malignant tumour in a man’s prostate gland. This walnut-shaped gland, which is about four centimetres in size, is part of the reproductive system; it is situated directly beneath the bladder, where it forms a ring around the urethra, and is adjacent to the rectum at the back. Its main function is to produce part of the seminal fluid that carries the sperm, and the urinary and seminal ducts converge in this area. In addition to seminal fluid, the prostate also produces prostate-specific antigen (PSA), which can be detected in the blood and where an elevated level may indicate prostate cancer. The growth and function of the prostate are regulated by the male sex hormone testosterone. Changes in the prostate occur in almost one in two men from the age of 50 onwards. These changes do not always indicate prostate cancer. A benign enlargement of the prostate, known as benign prostatic hyperplasia (BPH), is also common; this narrows the urethra, leading to symptoms such as a weaker urine stream and a more frequent urge to urinate. In contrast, prostate cancer is a malignant tumour that usually only causes symptoms when passing urine once the tumour has already spread. Prostate cancer is most common in men aged 70 and over. The probability of still being alive five years after diagnosis is the second highest of all cancers. So people do not usually die from this cancer, as prostate cancer often has a favourable prognosis. Furthermore, thanks to improved screening and the measurement of PSA levels, the cancer can now often be diagnosed at an early stage, meaning that the chances of a complete cure have also improved. 
Causes and risk factors
The exact causes are not fully understood, but there are certain factors that increase the risk of developing prostate cancer. The most important of these is advancing age: the incidence of prostate cancer rises with age, and the disease is usually detected in older men. Family history also plays a role: the more family members who have or have had prostate cancer, and the younger they were at the time of diagnosis, the higher the risk for male relatives. For this reason, regular prostate cancer screening is strongly recommended for men aged 45 and over, and for those with an increased family risk from the age of 40. It is also known that ethnic factors play a role: men from sub-Saharan Africa are more likely to develop the disease than Europeans, whilst Asians are rarely affected. In addition, other risk factors such as local inflammatory processes or obesity are under discussion, but the links have not yet been sufficiently scientifically proven.
Symptoms
In the early stages, there are no typical symptoms and those affected usually do not notice anything at first. Only when the tumour has grown large enough to press on the urethra or form metastases outside the prostate may the following symptoms occur:
- an increased urge to urinate, particularly at night
- difficulty starting to urinate
- inability to urinate
- weak or interrupted urine flow
- painful ejaculation
- Blood in the urine or semen
- Severe pain in the lower back, pelvis, hips or thighs
- Weaker erections or impotence
- reduced volume of ejaculate
Please note: In most cases, these are also symptoms of a benign enlarged prostate. If one or more of these symptoms occur, it is advisable to consult a doctor to determine the cause.
Prostate cancer – diagnosis
Diagnosis involves a digital rectal examination (DRE) and a blood test to measure PSA levels. PSA (prostate-specific antigen) is a protein produced exclusively by prostate cells. Cancer cells in the prostate can produce around ten times as much PSA as normal prostate cells, but: not every increase in the PSA level necessarily indicates prostate cancer. As PSA results are often borderline or difficult to interpret, the PSA level frequently needs to be monitored over a longer period, usually for one year. Further investigations to confirm the diagnosis include ultrasound-guided prostate biopsy, as well as imaging studies and bone scintigraphy to determine the extent of the tumour.
Treatment of prostate cancer
Once a diagnosis of prostate cancer has been confirmed, the next step is to draw up a treatment plan. The histological findings, the extent of the tumour, the patient’s age, his state of health and other individual factors all play a role in this. The treatment chosen depends largely on whether the tumour is still confined to the prostate or has already spread to surrounding tissue and formed metastases in lymph nodes and other organ systems. In principle, there are numerous options, the most important of which are as follows: Watchful waiting: This strategy is highly valued in the management of prostate cancer, partly because this cancer often grows slowly and does not always pose an immediate threat to the patient, and because an increasing number of tumours are detected at a very early stage, meaning that treating doctors must decide whether the benefits of treatment are proportionate to its risks and side effects. A distinction is made between two different approaches: in ‘watchful waiting’, the tumour is not treated initially. Affected men contact their doctor themselves if symptoms develop. These are then treated if necessary. However, a cure is not the aim here. This strategy is primarily suitable for patients whose estimated life expectancy is less than ten years or for whom curative treatment is not possible due to underlying medical conditions. With active surveillance, patients are closely monitored. If the tumour remains stable, no treatment is given. However, if the disease progresses, a radical prostatectomy (complete removal of the prostate and seminal vesicles) or radiotherapy is usually carried out. Surgery: If the cancer is confined to the prostate, it can be removed by a radical prostatectomy (removal of the prostate and surrounding tissue), for which there are various surgical techniques. The prospects of a permanent cure are very good, particularly if the tumour can be removed in its entirety. However, undesirable side effects such as loss of erectile function and urinary incontinence may sometimes occur. Radiotherapy: A distinction is made between two methods: In percutaneous radiotherapy (external beam radiotherapy through the skin), the radiation source is directed from outside the body at the tumour tissue, whilst the surrounding tissue is largely spared. This procedure is recommended for locally confined prostate cancer and is comparable to surgery in terms of effectiveness. In brachytherapy (internal radiation therapy), either low-level radioactive seeds or radiation sources are inserted into the prostate, where they emit radiation. Depending on the method used, these procedures are recommended for prostate cancer with a low-risk profile or for medium- and high-risk prostate cancer, in combination with subsequent percutaneous radiotherapy. Here too, side effects such as impotence, urinary incontinence and other undesirable consequences may occur – albeit less frequently than with surgery. Focal therapy: In this approach, it is not the entire prostate that is treated, but only the cancerous lesions. These are specifically destroyed, for example using ultrasound waves. This means that the tumour is made light-sensitive with the aid of medication and then irradiated, causing it to be ‘cooked’ or suffer a ‘cold shock’ and die off. Surrounding tissue is spared in these procedures, which is why side effects are also less severe. However, focal therapies are only suitable for patients with localised prostate cancer. It is also not yet conclusively clear whether these therapies are as effective as radical prostatectomy and radiotherapy. Hormone therapy: This treatment aims to lower testosterone levels (testosterone promotes the growth of prostate cancer cells) and thus inhibit the progression of the disease – often for many months or even years. It cannot cure the disease on its own, but this form of treatment has its place in the management of advanced prostate cancer with metastases, locally advanced prostate cancer (in addition to radiotherapy) or early-stage prostate cancer, when other treatments are not an option. Hormone deprivation can also help to alleviate the symptoms of the disease. It is also important to note that hormone therapy loses its effectiveness over time, leading to resistance to treatment. Chemotherapy: It plays a relatively minor role in prostate cancer, as this cancer is not as sensitive to it as other tumours. It is primarily used when the tumour has already metastasised and is often combined with hormone therapy. Another benefit of chemotherapy for prostate cancer is its effectiveness in treating tumour- and metastasis-related symptoms, such as pain. Furthermore, intensive research is currently being carried out into further treatments for prostate cancer in particular, and there are numerous new approaches and experimental therapies, many of which are still being tested in clinical trials. Whether and under what conditions these might be suitable for individual patients should ideally be discussed with the treating doctors.
Prostate cancer and sexuality
Maintaining a healthy sex life during and after treatment is naturally a key concern for most patients. Although new treatments such as nerve-sparing surgery or minimally invasive radiotherapy cater to this wish, preserving sexual function can be problematic with certain treatment approaches. You should therefore always discuss this with your doctor.
Screening
Austrian urologists recommend starting prostate cancer screening from the age of 45. For men with an increased family history of the disease, screening should begin as early as 40. The screening comprises a digital rectal examination by the doctor, a blood test to measure PSA levels, and an ultrasound scan. Depending on the results, the next screening appointment will then be scheduled. You may also be interested in: Cancer: All screening tests at a glance